Genesis Mission: $5B in grants announced
The White House announced approximately $5 billion in Genesis Mission grants at a recent summit, with many focused on biotech and AI for science.
Snapshot · Moonshots with Peter Diamandis
Michael Kratsios on the New Golden Age of American Science | EP #276
Explore episode
Aug 4, 2026
Where this was said
Longevity, Biotech, and What's Missing From the Golden Age Report
At 52:13 · chapter starts 51:45
Peter notes that Kratsios's six national technology missions — AI, quantum, commercial fusion, lunar exploration, robotics, and next-generation semiconductors — conspicuously omit longevity and biotech. Kratsios acknowledges this directly, noting that longevity wasn't explicitly listed, though much of the biotech work is nested under the Genesis Mission's AI-for-science umbrella. He confirms that roughly $5 billion in Genesis Mission grants were announced at a recent summit, with many focused on biotech applications. The conversation then surfaces Dario Amodei's claim of potentially doubling human lifespan in 5–10 years, and Demis Hassabis's assertion — delivered to Kratsios personally — that AI could cure all diseases within a decade. Kratsios recalls being genuinely unsure whether Hassabis was joking. He was not.
Similar snapshots
540M years ago: first animal vision
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
50% of cortex involved in vision
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Human 6-year-olds learn tens of thousands of object categories
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
~3% of FDA drugs have unclear mechanisms
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
30–50% of phase 1 drugs fail to reach phase 2
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
BPC-157 published work: >80% from one group
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
~100 approved peptide drugs; ~150 in trials
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
BPC-157 founder withheld screening method
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
Brain barely distinguishes imagined vs real
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
